Goodman & Gilman, Pharmacological Basis of Therapeutics.6th Edition, 1980. Macmillan, New York. Eds, Goodman-GilmanAlfred, GoodmanLouis F., GilmanAlfred.
4.
ZaskeD.E., CipolleR.J., StrateR.J.: Gentamicin dosage requirements wide interpatient variations in 242 surgery patients with normal renal function.Surgery 87:2: 164–169, 1980.
5.
ZaskeD.E., CipolleR.J., StrateR.G., DickesW.F.: Increased gentamicin dosage requirements: rapid elimination in 249 gynecology patients. Am. J. Obstet Gynecol.139:8: 896–900, 1981.
6.
SchentagJ.J.: Aminoglycoside tissue accumulation: a comparison between gentamicin and tobramycin. Symposium: Assessment of Aminoglycoside Toxicity, Burgenstock, Switzerland, September 24–25, 1977, p. 26–31.
7.
AshS.R., MillikanM.D.: Optimizing tobramycin therapy in a hemodialysis patient.Inter. J. Artif. Organs 5:4: 279–280, 1982.
8.
SketrisI.S., SkoutakisV.A.: Dialysis and hemoperfusion of drugs and toxins.Clin. Toxicol. Consult.3: 100–117, 1981.
9.
JuskoW.J., LewisG.P., SchmittG.W.: Ampicillen and hetacillen pharmacokinetics in normal and anephric subjects.Clin. Pharmacol. Therap.14: 90–98, 1973.
10.
AronoffG.A..: Moxalactam pharmacokinetics during hemodialysis.Antimicrob. Agent Chemoter.19: 575–577, 1981.
11.
NattelS..: Procainamide acetylation and disposition in dialysis patients. Clin Invest.Med.2: 5–11, 1979.
12.
GibsonT.P., MatusikE., BriggsW.A.: N-acetyl procainamide levels in patients with end-stage renal failure.Clin. Pharmacol. Ther.19: 206–212, 1976.
13.
StecG.P..: N-acetyl procainamide pharmacokinetics in functionally anephric patients before and after perturbation by hemodialysis.Clin. Pharmacol. Ther.26: 618–628, 1979.
14.
LatosD.L., BryanC.S., StoneW.J.: Carbenicillen therapy in patients with normal and impaired renal function.Clin. Pharmacol.17: 692–700, 1975.
15.
PizzellaK.M..: Removal of cimetidine by peritoneal dialysis, hemodialysis, and charcoal hemoperfusion.Ther drug Monitoring2: 273–281, 1980.
16.
HerreraJ., VukovichR.A., GriffithD.L.: Elimination of nadolol by patients with renal impairment.Br. J. Clin. Pharmacol.7: 227–231Suppl. 2, 1979.
17.
GibsonT.P..: Elimination of procainamide in end-stage renal failure.Clin. Pharmacol. Ther.17: 321–329, 1975.
18.
KampfD..: Effects of impaired renal function, hemodialysis, and peritoneal dialysis on the pharmacokinetics of mezlocillin.Antimicrob. Agents Chemoter.18: 81–87, 1980.
19.
ChodosJ..; pharmacokinetics of intravenous cefotoxime in patients undergoing hemodialysis.Ther Drug Monitoring3: 71–74, 1981.
20.
WheltonA..: Pharmacokinetics of doxycycline in the absence of renal function.Kidney Int.:5: 365–371, 1974.
21.
BlouinR.A..: Chloramphenicol hemodialysis clearance.Ther Drug Monitoring2: 351–354, 1980.
22.
JacobiJ..: Hemodialysis clearance of total and unbound lidocaine.Clin. Pharmacy2: 54–57, 1983.
23.
VaziriN.D., SaikiJ.K., HughesW.: Clearance of lidocaine by hemodialysis.So. Med. J.72: 1567–1568, 1979.
24.
LowenthalD.T..Pharmacokinetics of oral propanolol in chronic renal disease.Clin. Pharmacol. Ther.16: 761–769, 1974.
25.
AdirJ..: Pharmacokinetics of bretylium in renal insufficiency.NEJM300: 1390–1391, 1979.
26.
GibsonT.P., NelsonH.A.: Drug kinetics and artificial kidneys.Clin. Pharmacokinetics2: 403–426, 1977.
27.
Kreeftj.H..: Metronidazole kinetics in dialysis patients.Surgery93: 149–153, 1983.
